Company profile for Vyera Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Vyera Pharmaceuticals is focused on developing therapies specifically targeted to treat patients suffering from serious and neglected diseases with high unmet needs. One of Vyera’s areas of focus is toxoplasmosis. Vyera provides support to programs that assist patients who may have difficulty affording their treatment and gives discounts to organizations that provide care to underserved patients. Toxoplasmosis is considered ...
Vyera Pharmaceuticals is focused on developing therapies specifically targeted to treat patients suffering from serious and neglected diseases with high unmet needs. One of Vyera’s areas of focus is toxoplasmosis. Vyera provides support to programs that assist patients who may have difficulty affording their treatment and gives discounts to organizations that provide care to underserved patients. Toxoplasmosis is considered a neglected parasitic infection that has been targeted as a priority for public health. Vyera's discovery program is identifying novel drug candidates in hopes of creating a treatment.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
600 Third Avenue, 10th Floor New York, NY 10016
Telephone
Telephone
+1 212.202.5935
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/tilde-sciences-acquires-daraprim-and-vecamyl-from-vyera-pharmaceuticals-302008403.html

PR NEWSWIRE
07 Dec 2023

https://www.prnewswire.com/news-releases/vyera-pharmaceuticals-llc-and-phoenixus-ag-sign-asset-purchase-agreement-to-sell-rights-to-daraprim-and-vecamyl-301890830.html

PR NEWSWIRE
01 Aug 2023
Shkreli's former company Vyera files for bankruptcy
Shkreli's former company Vyera files for bankruptcy

11 May 2023

// Fraiser Kansteiner FIERCE PHARMA

https://www.fiercepharma.com/pharma/martin-shkrelis-former-company-vyera-files-bankruptcy

Fraiser Kansteiner FIERCE PHARMA
11 May 2023

https://news.bloomberglaw.com/securities-law/pharma-bro-shkreli-fails-to-pause-industry-bar-pending-appeal

BLOOMBERG
27 Apr 2022
Vyera has settled with FTC for $40M as Shkreli's trial looms
Vyera has settled with FTC for $40M as Shkreli's trial looms

08 Dec 2021

// F. Kansteiner FIERCEPHARMA

https://www.fiercepharma.com/pharma/shkreli-s-former-company-vyera-settles-for-40m-daraprim-antitrust-case-but-pharma-bro-has

F. Kansteiner FIERCEPHARMA
08 Dec 2021

https://endpts.com/martin-shkreli-to-go-toe-to-toe-with-new-ftc-chair-over-daraprim-price-spikes/

Max Gelman ENDPTS
11 Sep 2021

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty